LIXTE BIOTECHNOLOGY HOLDINGS, INC.

The Company is a clinical-stage biopharmaceutical and proton cancer therapy company that identifies new targets for cancer drug development and develops and commercializes cancer therapies. Its drug product pipeline primarily focuses on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic agents, radiation, immune checkpoint blockers, and other cancer therapies. The Company is clinically developing LB-100, a specific protein phosphatase inhibitor that has demonstrated clinical anti-cancer activity. LB-100 is currently being tested in clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon Cancer, and Advanced Soft Tissue Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, which are cancers of neural tissue. It has also been shown to enhance the effectiveness of commonly used anti-cancer drugs in animal models of melanoma, breast cancer, and sarcoma at doses that do not significantly increase toxicity. The Company is the majority shareholder of Liora Technologies Europe Ltd., which develops electronically controlled proton therapy systems for treating tumors in various cancer types. Liora's proprietary technology, known as LiGHT System (Linac for Image Guided Hadron Therapy), complements the Company's pharmaceutical business and ongoing clinical trials with LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.